Articles tagged with Platelet Derived Growth Factor Receptors
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
A team of researchers has discovered genetic changes in glioblastoma, a common type of primary brain cancer, that contribute to its aggressiveness. The study found that tumors with rearrangements in receptor genes are more common than previously thought, suggesting new targets for therapies.
Several anticancer drugs have been linked to heart failure in patients, with research now shedding light on the role of PDGFR-beta. In mouse models, inhibition of PDGFR-beta signaling was found to exacerbate heart failure under pressure overload conditions.
Researchers found that cancer drugs targeting PDGFR can impair the heart's ability to respond to stress, increasing risk of heart failure. The study suggests aggressive control of high blood pressure may reduce cardiac toxicity caused by these agents.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.